Dr. Reed’s research interest focuses on the prediction of conventional chemotherapy efficacy in non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) using ex vivo assays and xenograft models. The research of Dr. Reed’s group is conducted in Dr. Altiok’s laboratory in close collaboration and is focused on biomarker discovery and validation in order to predict clinical benefit in NRSTS. The work has focused on creating a panel of representative NRSTS xenografts from fresh, untreated human sarcomas and serially transplanting them through generations in immunodeficient mice. Furthermore, fresh human tissue is tested ex vivo in the presence of clinically relevant chemotherapeutic agents and molecular pathways of DNA damage, cell cycle arrest and apoptosis; analysis includes, but is not limited to, PARP cleavage, gammaH2AX, and Rb. Currently, through support from the Sarcoma Foundation of America, the xenografts are being treated in vivo with agents or combinations with correlative ex vivo results.